References [1]  Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373–92. [2]  Institute ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

In the evolving field of neurodegenerative medicine, the challenge is not merely discovering new treatments but ensuri ...

The poster titled, A Phase Ib Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of the Novel Neuroplastogen DLX-001 in Participants with Major Depressive Disorder: Interim Findings, was ...

Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is effective at detecting a pharmacodynamic ...

In a nutshell One injection of zilebesiran every six months could replace daily blood pressure pills for some patients ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Guidance language now reflects anticipation of FDA decision upon post-market study plan approval, compared to prior uncertainty about regulatory timing. The focus on US commercialization and sales ...

Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with ...

The World Health Organization (WHO) today posted an outbreak notice about a rise in COVID activity in three of its regions, ...

The online BREAKING-ICE App, where ICE stands for informative censoring exploration, is designed to visually demonstrate the impact of informative censoring on trial outcomes. The app aims to ...